Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-

Science Translational Medicine

Volumn 10, Issue 424, 2018, Pages

  Lan, Yan ^a   Zhang, Dong ^a   Xu, Chunxiao ^a   Hance, Kenneth W ^a,b   Marelli, Bo ^a   Qi, Jin ^a   Yu, Huakui ^a   Qin, Guozhong ^a   Sircar, Aroop ^a   Hernández, Vivian M ^a   Jenkins, Molly H ^a   Fontana, Rachel E ^a   Deshpande, Amit ^a   Locke, George ^a   Sabzevari, Helen ^a,c   Radvanyi, Laszlo ^a   Lo, Kin Ming ^a  

^a EMD Serono Research Institute   (United States)

^b GLAXOSMITHKLINE   (United States)

^c INTREXON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; HYBRID PROTEIN; M 7824; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACOKINETIC ASSAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY; ANIMAL; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; IMMUNOTHERAPY; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 85040863373     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan5488     Document Type: Article

References (105)

1. I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
2. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
3. L. Zitvogel, G. Kroemer, Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223–1225 (2012).
4. D. F. McDermott, M. B. Atkins, PD-1 as a potential target in cancer therapy. Cancer Med. 2, 662–673 (2013).
5. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 3360–3365 (2007).
6. Y. Qing, Q. Li, T. Ren, W. Xia, Y. Peng, G. L. Liu, H. Luo, Y. X. Yang, X. Y. Dai, S. F. Zhou, D. Wang, Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des. Devel. Ther. 9, 901–909 (2015).
7. J. S. Weber, S. P. D’Angelo, D. Minor, F. S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N. I. Khushalani, W. H. Miller Jr., C. D. Lao, G. P. Linette, L. Thomas, P. Lorigan, K. F. Grossmann, J. C. Hassel, M. Maio, M. Sznol, P. A. Ascierto, P. Mohr, B. Chmielowski, A. Bryce, I. M. Svane, J.-J. Grob, A. M. Krackhardt, C. Horak, A. Lambert, A. S. Yang, J. Larkin, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
8. M. A. Postow, J. Chesney, A. C. Pavlick, C. Robert, K. Grossmann, D. McDermott, G. P. Linette, N. Meyer, J. K. Giguere, S. S. Agarwala, M. Shaheen, M. S. Ernstoff, D. Minor, A. K. Salama, M. Taylor, P. A. Ott, L. M. Rollin, C. Horak, P. Gagnier, J. D. Wolchok, F. S. Hodi, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
9. C. Robert, J. Schachter, G. V. Long, A. Arance, J. J. Grob, L. Mortier, A. Daud, M. S. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. U. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, H. Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas, Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
10. H. Borghaei, L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, L. Q. Chow, E. E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaufl, O. Arrieta, M. A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D. E. Gerber, S. N. Gettinger, C. M. Rudin, N. Rizvi, L. Crino, G. R. Blumenschein Jr., S. J. Antonia, C. Dorange, C. T. Harbison, F. Graf Finckenstein, J. R. Brahmer, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
11. R. S. Herbst, P. Baas, D.-W. Kim, E. Felip, J. L. Pérez-Gracia, J.-Y. Han, J. Molina, J.-H. Kim, C. D. Arvis, M.-J. Ahn, M. Majem, M. J. Fidler, G. De Castro, M. Garrido, G. M. Lubiniecki, Y. Shentu, E. Im, M. Dolled-Filhart, E. B. Garon, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387, 1540–1550 (2016).
12. A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. von Pawel, S. M. Gadgeel, T. Hida, D. M. Kowalski, M. C. Dols, D. L. Cortinovis, J. Leach, J. Polikoff, C. Barrios, F. Kabbinavar, O. A. Frontera, F. De Marinis, H. Turna, J. S. Lee, M. Ballinger, M. Kowanetz, P. He, D. S. Chen, A. Sandler, D. R. Gandara, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).
13. R. J. Motzer, B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, D. Castellano, T. K. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. C. Gauler, T. Ueda, Y. Tomita, F. A. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. S. Simon, L.-A. Xu, I. M. Waxman, P. Sharma; CheckMate 025 Investigators, Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
14. H. L. Kaufman, J. Russell, O. Hamid, S. Bhatia, P. Terheyden, S. P. D’Angelo, K. C. Shih, C. Lebbé, G. P. Linette, M. Milella, I. Brownell, K. D. Lewis, J. H. Lorch, K. Chin, L. Mahnke, A. von Heydebreck, J.-M. Cuillerot, P. Nghiem, Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374–1385 (2016).
15. J. E. Rosenberg, J. Hoffman-Censits, T. Powles, M. S. van der Heijden, A. V. Balar, A. Necchi, N. Dawson, P. H. O’Donnell, A. Balmanoukian, Y. Loriot, S. Srinivas, M. M. Retz, P. Grivas, R. W. Joseph, M. D. Galsky, M. T. Fleming, D. P. Petrylak, J. L. Perez-Gracia, H. A. Burris, D. Castellano, C. Canil, J. Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G. M. Frampton, N. Cui, S. Mariathasan, O. Abidoye, G. D. Fine, R. Dreicer, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
16. P. Sharma, M. Retz, A. Siefker-Radtke, A. Baron, A. Necchi, J. Bedke, E. R. Plimack, D. Vaena, M.-O. Grimm, S. Bracarda, J. A. Arranz, S. Pal, C. Ohyama, A. Saci, X. Qu, A. Lambert, S. Krishnan, A. Azrilevich, M. D. Galsky, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312–322 (2017).
17. M. S. Farina, K. T. Lundgren, J. Bellmunt, Immunotherapy in urothelial cancer: Recent results and future perspectives. Drugs 77, 1077–1089 (2017).
18. R. L. Ferris, G. Blumenschein Jr., J. Fayette, J. Guigay, A. D. Colevas, L. Licitra, K. Harrington, S. Kasper, E. E. Vokes, C. Even, F. Worden, N. F. Saba, L. C. Iglesias Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. J. Geese, J. Kopit, J. W. Shaw, M. L. Gillison, Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
19. J. Bauml, T. Y. Seiwert, D. G. Pfister, F. Worden, S. V. Liu, J. Gilbert, N. F. Saba, J. Weiss, L. Wirth, A. Sukari, H. Kang, M. K. Gibson, E. Massarelli, S. Powell, A. Meister, X. Shu, J. D. Cheng, R. Haddad, Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J. Clin. Oncol. 35, 1542–1549 (2017).
20. I. Melero, D. M. Berman, M. A. Aznar, A. J. Korman, J. L. Perez Gracia, J. Haanen, Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457–472 (2015).
21. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, C. L. Cowey, C. D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P. F. Ferrucci, A. Hill, J. Wagstaff, M. S. Carlino, J. B. Haanen, M. Maio, I. Marquez-Rodas, G. A. McArthur, P. A. Ascierto, G. V. Long, M. K. Callahan, M. A. Postow, K. Grossmann, M. Sznol, B. Dreno, L. Bastholt, A. Yang, L. M. Rollin, C. Horak, F. S. Hodi, J. D. Wolchok, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
22. R. J. Akhurst, A. Hata, Targeting the TGF signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790–811 (2012).
23. M. O. Li, R. A. Flavell, Contextual regulation of inflammation: A duet by transforming growth factor- and interleukin-10. Immunity 28, 468–476 (2008).
24. S. H. Wrzesinski, Y. Y. Wan, R. A. Flavell, Transforming growth factor- and the immune response: Implications for anticancer therapy. Clin. Cancer Res. 13, 5262–5270 (2007).
25. L. J. A. C. Hawinkels, H. W. Verspaget, W. van Duijn, J. M. van der Zon, K. Zuidwijk, F. J. G. M. Kubben, J. H. Verheijen, D. W. Hommes, C. B. H. W. Lamers, C. F. M. Sier, Tissue level, activation and cellular localisation of TGF-1 and association with survival in gastric cancer patients. Br. J. Cancer 97, 398–404 (2007).
26. D. R. Principe, J. A. Doll, J. Bauer, B. Jung, H. G. Munshi, L. Bartholin, B. Pasche, C. Lee, P. J. Grippo, TGF-: Duality of function between tumor prevention and carcinogenesis. J. Natl. Cancer Inst. 106, djt369 (2014).
27. J. J. Lebrun, The dual role of TGF in human cancer: From tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 381428 (2012).
28. C. Neuzillet, A. Tijeras-Raballand, R. Cohen, J. Cros, S. Faivre, E. Raymond, A. de Gramont, Targeting the TGF pathway for cancer therapy. Pharmacol. Ther. 147, 22–31 (2015).
29. J. M. Yingling, K. L. Blanchard, J. S. Sawyer, Development of TGF- signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011–1022 (2004).
30. Y. Pang, S. K. Gara, B. R. Achyut, Z. Li, H. H. Yan, C.-P. Day, J. M. Weiss, G. Trinchieri, J. C. Morris, L. Yang, TGF- signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 3, 936–951 (2013).
31. D. Gate, M. Danielpour, J. Rodriguez Jr., G.-B. Kim, R. Levy, S. Bannykh, J. J. Breunig, S. M. Kaech, R. A. Flavell, T. Town, T-cell TGF- signaling abrogation restricts medulloblastoma progression. Proc. Natl. Acad. Sci. U.S.A. 111, E3458–E3466 (2014).
32. M. O. Li, S. Sanjabi, R. A. Flavell, Transforming growth factor- controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455–471 (2006).
33. M. O. Li, Y. Y. Wan, R. A. Flavell, T cell-produced transforming growth factor-1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26, 579–591 (2007).
34. D. A. Thomas, J. Massague, TGF- directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).
35. S. Viel, A. Marcais, F. S. Guimaraes, R. Loftus, J. Rabilloud, M. Grau, S. Degouve, S. Djebali, A. Sanlaville, E. Charrier, J. Bienvenu, J. C. Marie, C. Caux, J. Marvel, L. Town, N. D. Huntington, L. Bartholin, D. Finlay, M. J. Smyth, T. Walzer, TGF- inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016).
36. S. L. Topalian, C. G. Drake, D. M. Pardoll, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).
37. W. Hugo, J. M. Zaretsky, L. Sun, C. Song, B. H. Moreno, S. Hu-Lieskovan, B. Berent-Maoz, J. Pang, B. Chmielowski, G. Cherry, E. Seja, S. Lomeli, X. Kong, M. C. Kelley, J. A. Sosman, D. B. Johnson, A. Ribas, R. S. Lo, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 168, 542 (2017).
38. H. Y. Lin, X.-F. Wang, E. Ng-Eaton, R. A. Weinberg, H. F. Lodish, Expression cloning of the TGF- type II receptor, a functional transmembrane serine/threonine kinase. Cell 68, 775–785 (1992).
39. K. Krasagakis, D. Tholke, B. Farthmann, J. Eberle, U. Mansmann, C. E. Orfanos, Elevated plasma levels of transforming growth factor (TGF)-1 and TGF-2 in patients with disseminated malignant melanoma. Br. J. Cancer 77, 1492–1494 (1998).
40. F. Kong, R. L. Jirtle, D. H. Huang, R. W. Clough, M. S. Anscher, Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86, 1712–1719 (1999).
41. A. J. Vandeveer, J. K. Fallon, R. Tighe, H. Sabzevari, J. Schlom, J. W. Greiner, Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti–PD-L1 immune checkpoint inhibitor. Cancer Immunol. Res. 4, 452–462 (2016).
42. J. Won, H. Kim, E. J. Park, Y. Hong, S.-J. Kim, Y. Yun, Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor receptor therapy. Cancer Res. 59, 1273–1277 (1999).
43. H. Y. Lin, A. Moustakas, P. Knaus, R. G. Wells, Y. I. Henis, H. F. Lodish, The soluble exoplasmic domain of the type II transforming growth factor (TGF)- receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF- ligands. J. Biol. Chem. 270, 2747–2754 (1995).
44. L. A. Van Aarsen, D. R. Leone, S. Ho, B. M. Dolinski, P. E. McCoon, D. J. LePage, R. Kelly, G. Heaney, P. Rayhorn, C. Reid, K. J. Simon, G. S. Horan, N. Tao, H. A. Gardner, M. M. Skelly, A. M. Gown, G. J. Thomas, P. H. Weinreb, S. E. Fawell, S. M. Violette, Antibody-mediated blockade of integrin v6 inhibits tumor progression in vivo by a transforming growth factor-–regulated mechanism. Cancer Res. 68, 561–570 (2008).
45. S. R. Gordon, R. L. Maute, B. W. Dulken, G. Hutter, B. M. George, M. N. McCracken, R. Gupta, J. M. Tsai, R. Sinha, D. Corey, A. M. Ring, A. J. Connolly, I. L. Weissman, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499 (2017).
46. M. Angelova, P. Charoentong, H. Hackl, M. L. Fischer, R. Snajder, A. M. Krogsdam, M. J. Waldner, G. Bindea, B. Mlecnik, J. Galon, Z. Trajanoski, Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).
47. G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A. C. Obenauf, H. Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, W. H. Fridman, C. Becker, F. Pages, M. R. Speicher, Z. Trajanoski, J. Galon, Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
48. A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, P. Tamayo, The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
49. J. Lieberman, The ABCs of granule-mediated cytotoxicity: New weapons in the arsenal. Nat. Rev. Immunol. 3, 361–370 (2003).
50. A. Calon, D. V. F. Tauriello, E. Batlle, TGF-beta in CAF-mediated tumor growth and metastasis. Semin. Cancer Biol. 25, 15–22 (2014).
51. S. Kakarla, X.-T. Song, S. Gottschalk, Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4, 1129–1138 (2012).
52. H. C. Dancea, M. M. Shareef, M. M. Ahmed, Role of radiation-induced TGF-beta signaling in cancer therapy. Mol. Cell. Pharmacol. 1, 44–56 (2009).
53. S. Biswas, M. Guix, C. Rinehart, T. C. Dugger, A. Chytil, H. L. Moses, M. L. Freeman, C. L. Arteaga, Inhibition of TGF- with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305–1313 (2007).
54. M. Luo, L. Fu, The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: Some chemotherapeutical drugs may finally work through immune response. Oncotarget 7, 29794–29803 (2016).
55. S. J. Dovedi, A. L. Adlard, G. Lipowska-Bhalla, C. McKenna, S. Jones, E. J. Cheadle, I. J. Stratford, E. Poon, M. Morrow, R. Stewart, H. Jones, R. W. Wilkinson, J. Honeychurch, T. M. Illidge, Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458–5468 (2014).
56. L. Deng, H. Liang, B. Burnette, M. Beckett, T. Darga, R. R. Weichselbaum, Y.-X. Fu, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).
57. B. Bierie, H. L. Moses, Tumour microenvironment: TGF: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520 (2006).
58. J. Massague, TGF in cancer. Cell 134, 215–230 (2008).
59. L. Yang, Y. Pang, H. L. Moses, TGF- and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220–227 (2010).
60. M. Yu, P. Trobridge, Y. Wang, S. Kanngurn, S. M. Morris, S. Knoblaugh, W. M. Grady, Inactivation of TGF- signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene 33, 1538–1547 (2014).
61. A. Beldi-Ferchiou, M. Lambert, S. Dogniaux, F. Vely, E. Vivier, D. Olive, S. Dupuy, F. Levasseur, D. Zucman, C. Lebbe, D. Sene, C. Hivroz, S. Caillat-Zucman, PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7, 72961–72977 (2016).
62. D. M. Benson Jr., C. E. Bakan, A. Mishra, C. C. Hofmeister, Y. Efebera, B. Becknell, R. A. Baiocchi, J. Zhang, J. Yu, M. K. Smith, C. N. Greenfield, P. Porcu, S. M. Devine, R. Rotem-Yehudar, G. Lozanski, J. C. Byrd, M. A. Caligiuri, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286–2294 (2010).
63. + T cell priming through PD-1/PD-L1 interactions with dendritic cells. J. Immunol. 197, 953–961 (2016).
64. K. E. Pauken, E. J. Wherry, Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265–276 (2015).
65. E. B. Wilson, J. J. El-Jawhari, A. L. Neilson, G. D. Hall, A. A. Melcher, J. L. Meade, G. P. Cook, Human tumour immune evasion via TGF- blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLOS ONE 6, e22842 (2011).
66. R. Trotta, J. Dal Col, J. Yu, D. Ciarlariello, B. Thomas, X. Zhang, J. Allard II, M. Wei, H. Mao, J. C. Byrd, D. Perrotti, M. A. Caligiuri, TGF- utilizes SMAD3 to inhibit CD16-mediated IFN- production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784–3792 (2008).
67. R. H. Rouce, H. Shaim, T. Sekine, G. Weber, B. Ballard, S. Ku, C. Barese, V. Murali, M.-F. Wu, H. Liu, E. J. Shpall, C. M. Bollard, K. R. Rabin, K. Rezvani, The TGF-/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia 30, 800–811 (2016).
68. R. Castriconi, C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, A. Moretta, Transforming growth factor 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 100, 4120–4125 (2003).
69. W. Zou, J. D. Wolchok, L. Chen, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Trans. Med. 8, 328rv4 (2016).
70. T. J. Curiel, S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, O. David, M. Burow, A. Gordon, N. Dhurandhar, L. Myers, R. Berggren, A. Hemminki, R. D. Alvarez, D. Emilie, D. T. Curiel, L. Chen, W. Zou, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).
71. + T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci. Rep. 6, 38362 (2016).
72. A. Alsuliman, D. Colak, O. Al-Harazi, H. Fitwi, A. Tulbah, T. Al-Tweigeri, M. Al-Alwan, H. Ghebeh, Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Mol. Cancer 14, 149 (2015).
73. S. Tsutsumi, H. Saeki, Y. Nakashima, S. Ito, E. Oki, M. Morita, Y. Oda, S. Okano, Y. Maehara, Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 108, 1119–1127 (2017).
74. C.-Y. Ock, S. Kim, B. Keam, M. Kim, T. M. Kim, J.-H. Kim, Y. K. Jeon, J.-S. Lee, S. K. Kwon, J. H. Hah, T.-K. Kwon, D.-W. Kim, H.-G. Wu, M.-W. Sung, D. S. Heo, PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 7, 15901–15914 (2016).
75. J. M. David, C. Dominguez, K. K. McCampbell, J. L. Gulley, J. Schlom, C. Palena, A novel bifunctional anti-PD-L1/TGF- trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 6, e1349589 (2017).
76. A. Mazzocca, E. Fransvea, F. Dituri, L. Lupo, S. Antonaci, G. Giannelli, Down-regulation of connective tissue growth factor by inhibition of transforming growth factor blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51, 523–534 (2010).
77. S. Medicherla, L. Li, J. Y. Ma, A. M. Kapoun, N. J. Gaspar, Y.-W. Liu, R. Mangadu, G. O’Young, A. A. Protter, G. F. Schreiner, D. H. Wong, L. S. Higgins, Antitumor activity of TGF- inhibitor is dependent on the microenvironment. Anticancer Res 27, 4149–4157 (2007).
78. R. A. Evans, Y. C. Tian, R. Steadman, A. O. Phillips, TGF-1-mediated fibroblast-myofibroblast terminal differentiation—The role of Smad proteins. Exp. Cell Res. 282, 90–100 (2003).
79. C. Guido, D. Whitaker-Menezes, C. Capparelli, R. Balliet, Z. Lin, R. G. Pestell, A. Howell, S. Aquila, S. Ando, U. Martinez-Outschoorn, F. Sotgia, M. P. Lisanti, Metabolic reprogramming of cancer-associated fibroblasts by TGF- drives tumor growth: Connecting TGF- signaling with “Warburg-like” cancer metabolism and L-lactate production. Cell Cycle 11, 3019–3035 (2012).
80. M. J. Anderton, H. R. Mellor, A. Bell, C. Sadler, M. Pass, S. Powell, S. J. Steele, R. R. Roberts, A. Heier, Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916–924 (2011).
81. K. Garber, Companies waver in efforts to target transforming growth factor beta in cancer. J. Natl. Cancer Inst. 101, 1664–1667 (2009).
82. A. B. Roberts, N. S. Roche, T. S. Winokur, J. K. Burmester, M. B. Sporn, Role of transforming growth factor-beta in maintenance of function of cultured neonatal cardiac myocytes. Autocrine action and reversal of damaging effects of interleukin-1. J. Clin. Invest. 90, 2056–2062 (1992).
83. A. W. Tolcher, J. D. Berlin, J. Cosaert, J. Kauh, E. Chan, S. A. Piha-Paul, A. Amaya, S. Tang, K. Driscoll, R. Kimbung, S. R. Kambhampati, I. Gueorguieva, D. S. Hong, A phase 1 study of anti-TGF receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 79, 673–680 (2017).
84. M. E. Lacouture, J. C. Morris, D. P. Lawrence, A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, J. A. Berzofsky, F. J. Hsu, J. Guitart, Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64, 437–446 (2015).
85. J. L. Gulley, C. R. Heery, J. Schlom, R. A. Madan, L. Cao, E. Lamping, J. L. Marte, L. M. Cordes, O. Christensen, C. Helwig, J. Strauss, Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-, in advanced solid tumors. J. Clin. Oncol. 35, 3006 (2017).
86. F. Bouquet, A. Pal, K. A. Pilones, S. Demaria, B. Hann, R. J. Akhurst, J. S. Babb, S. M. Lonning, J. K. DeWyngaert, S. C. Formenti, M. H. Barcellos-Hoff, TGF1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 17, 6754–6765 (2011).
87. M. E. Hardee, A. E. Marciscano, C. M. Medina-Ramirez, D. Zagzag, A. Narayana, S. M. Lonning, M. H. Barcellos-Hoff, Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-. Cancer Res. 72, 4119–4129 (2012).
88. M. Zhang, S. Kleber, M. Rohrich, C. Timke, N. Han, J. Tuettenberg, A. Martin-Villalba, J. Debus, P. Peschke, U. Wirkner, M. Lahn, P. E. Huber, Blockade of TGF- signaling by the TGFR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71, 7155–7167 (2011).
89. C. Vanpouille-Box, J. M. Diamond, K. A. Pilones, J. Zavadil, J. S. Babb, S. C. Formenti, M. H. Barcellos-Hoff, S. Demaria, TGF is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232–2242 (2015).
90. H. E. Barker, J. T. E. Paget, A. A. Khan, K. J. Harrington, The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).
91. H. B. Stone, C. N. Coleman, M. S. Anscher, W. H. McBride, Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol. 4, 529–536 (2003).
92. J. M. Straub, J. New, C. D. Hamilton, C. Lominska, Y. Shnayder, S. M. Thomas, Radiation-induced fibrosis: Mechanisms and implications for therapy. J. Cancer Res. Clin. Oncol. 141, 1985–1994 (2015).
93. M. K. Callahan, M. A. Postow, J. D. Wolchok, CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front. Oncol. 4, 385 (2014).
94. H. Friess, Y. Yamanaka, M. Buchler, M. Ebert, H. G. Beger, L. I. Gold, M. Korc, Enhanced expression of transforming growth factor isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846–1856 (1993).
95. G. De Crescenzo, P. L. Pham, Y. Durocher, M. D. O’Connor-McCourt, Transforming growth factor-beta (TGF-) binding to the extracellular domain of the type II TGF- receptor: Receptor capture on a biosensor surface using a new coiled-coil capture system demonstrates that avidity contributes significantly to high affinity binding. J. Mol. Biol. 328, 1173–1183 (2003).
96. D. Wu, E. Lim, F. Vaillant, M.-L. Asselin-Labat, J. E. Visvader, G. K. Smyth, ROAST: Rotation gene set tests for complex microarray experiments. Bioinformatics 26, 2176–2182 (2010).
97. P. J. Hart, S. Deep, A. B. Taylor, Z. Shu, C. S. Hinck, A. P. Hinck, Crystal structure of the human TR2 ectodomain-TGF-3 complex. Nat. Struct. Biol. 9, 203–208 (2002).
98. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
99. D. Moiani, M. Salvalaglio, C. Cavallotti, A. Bujacz, I. Redzynia, G. Bujacz, F. Dinon, P. Pengo, G. Fassina, Structural characterization of a Protein A mimetic peptide dendrimer bound to human IgG. J. Phys. Chem. B 113, 16268–16275 (2009).
100. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
101. B. Li, C. N. Dewey, RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
102. R. Kolde, pheatmap: Pretty Heatmaps. R package version 1.0.8 (2015); https://cran.r-project.org/web/packages/pheatmap/index.html.
103. H. R. Koene, M. Kleijer, J. Algra, D. Roos, A. E. von dem Borne, M. de Haas, FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcRIIIa, independently of the FcRIIIa-48L/R/H phenotype. Blood 90, 1109–1114 (1997).
104. J. Wu, J. C. Edberg, P. B. Redecha, V. Bansal, P. M. Guyre, K. Coleman, J. E. Salmon, R. P. Kimberly, A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100, 1059–1070 (1997).
105. J. C. Yang, D. Perry-Lalley, The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J. Immunother. 23, 177–183 (2000).